GlassScriptPhysician profile
Panagiotis N Valilis
NPI 1033158480
$2,419.32
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $577 · 2021: $289 · 2022: $416.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $533.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $401.69 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $250.01 | 2022 | |
| Genentech USA, INC. | $190.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $178.11 | 2019-2022 | |
| Janssen Biotech, INC. | $168.95 | 2020 | |
| Astellas Pharma US INC | $127.50 | 2020 | |
| Alexion Pharmaceuticals, INC. | $120.35 | 2020 | |
| Kite Pharma, INC. | $105.59 | 2019 | |
| Amgen INC. | $101.18 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $28.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $23.83 | 2021 | |
| Verastem, INC. | $21.38 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $19.19 | 2020 | |
| Seagen INC. | $15.62 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Panagiotis Valilis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.